- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02766465
Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503) (STRIDE2)
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN 1503)
Study Overview
Status
Conditions
Detailed Description
This is a prospective phase II multi-center trial of hematopoietic stem cell transplantation or standard of care based on availability of HLA-matched related or unrelated donor after confirmation of clinical eligibility. In order to minimize bias assignment to either treatment arm, clinical eligibility to both treatment arms are similar and donor availability is not known at referral. HLA typing and donor search is initiated upon confirmation of clinical eligibility for the study. Additionally, all analyses of primary and secondary endpoints will follow the Intent-to-Treat principle to address potential bias introduced by participants with donors not proceeding to transplantation or those without a matched donor receiving transplantation with less well-matched donors.
The primary outcome is 2-year overall survival. Our hypothesis is that patients who receive bone marrow transplantation will experience early deaths but that this will plateau by 2 years after transplantation. Patients who receive standard of care will not experience early death but will succumb to their disease at a rate much higher than the general population. Therefore, the goal of the study is to establish that the difference in the proportion of patients surviving is not significantly more than 15% lower in the donor arm at 2-years after assignment to treatment arm.
Secondary endpoints will compare changes in sickle cell disease related events (pulmonary hypertension, cerebrovascular events, renal function, avascular necrosis, leg ulcer) and functional outcomes [6-minute walk distance (6MWD), health-related quality of life, cardiac function, pulmonary function, and mean pain intensity as assessed by a multidimensional electronic pain diary] from baseline to 2-years after assignment to treatment arms.
Additionally for patients assigned to the donor arm and expected to undergo transplantation, hematopoietic recovery, graft rejection, acute and chronic graft-versus-host disease, other significant transplant-related complications and disease-free survival will be reported.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- Benioff Children's Hospital at Oakland
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida Gainsville
-
Hollywood, Florida, United States, 33021
- Foundation for Sickle Cell Research/Florida Sickle Inc.
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Grady Memorial Hospital
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Augusta, Georgia, United States, 30912
- Augusta University Medical Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70118
- Children's Hospital of New Orleans
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Boston University
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute/Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02114
- Dana Farber Cancer Institute/Brigham & Women's Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University/St. Louis Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
Newark, New Jersey, United States, 07112
- Newark Beth Israel Medical Center
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center/Albert Einstein School of Medicine
-
Brooklyn, New York, United States, 11215
- New York Presbyterian Brooklyn Methodist Hospital
-
New Hyde Park, New York, United States, 11040
- Cohen Children's Medical Center
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27516
- University of North Carolina Hospital at Chapel Hill
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine/The Methodist Hospital
-
Houston, Texas, United States, 77030
- University of Texas/MD Anderson CRC
-
Houston, Texas, United States, 77004
- University of Texas Health Sciences Center
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 15 and < 41 years
Severe sickle cell disease [Hemoglobin SS (Hb SS), Hemoglobin SC (Hb SC) or Hemoglobin SBeta thalassemia (Hb Sβ) genotype] with at least 1 of the following manifestations (a-e):
- Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours;
- History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy);
- An average of three or more pain crises per year in the 2-year period preceding enrollment (required intravenous pain management in the outpatient or inpatient hospital setting). Clinical documentation of pain management in the inpatient or outpatient setting is required.
- Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusion events per year (in the 12 months before enrollment) to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
- An echocardiographic finding of tricuspid valve regurgitant jet (TRJ) velocity ≥ 2.7 m/sec.
- Ongoing high impact chronic pain on a majority of days per month for ≥ 6 months as defined as ONE or more of the following: Chronic pain without contributory SCD complications, OR Mixed pain type in which chronic pain is occurring at site(s) (arms, back, chest, or abdominal pain) unrelated to any sites associated with Contributory SCD complications (e.g. leg ulcers and/or avascular necrosis).
i. High impact chronic pain is identified as those reporting "severe interference" with life activities OR "usually or always" experiencing a limitation of their life or work activities including household chores. (See guidelines for identifying HICP in the BMT CTN 1503 Manual of Procedures) ii. Contributory SCD complications are defined as clinical signs (e.g. presence of leg ulcers) or clinical assessments (e.g. imaging confirmation of splenic infarct or avascular necrosis). Chronic pain attributed solely to contributory SCD complications is excluded.
Adequate physical function as measured by all of the following:
- Karnofsky/Lansky performance score ≥ 60
- Cardiac function: Left ventricular ejection fraction (LVEF) > 40%; or LV shortening fraction > 26% by cardiac echocardiogram or by Multi Gated Acquisition Scan (MUGA).
- Pulmonary function:
a. Pulse oximetry with a baseline O2 saturation of ≥ 85% b. Diffusing capacity of the lung for carbon monoxide (DLCO) > 40% (corrected for hemoglobin) d. Renal function: Serum creatinine ≤ 1.5 x the upper limit of normal for age as per local laboratory and 24 hour urine creatinine clearance >70 mL/min; or GFR > 70 mL/min/1.73 m2 by radionuclide Glomerular Filtration Rate (GFR).
e. Hepatic function:
- Serum conjugated (direct) bilirubin < 2x upper limit of normal for age as per local laboratory. Participants are not excluded if the serum conjugated (direct) bilirubin is >2x the upper limit of normal for age as per local laboratory and: There is evidence of a hyperhemolytic reaction after a recent RBC transfusion, OR there is evidence of moderate direct hyperbilirubinemia defined as direct serum bilirubin < 5 times ULN and not caused by underlying hepatic diseasePatients
- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 times upper limit of normal as per local laboratory.
Additional inclusion required for donor arm participants to proceed with transplant
- Liver MRI (≤ 90 days prior to initiation of transplant conditioning) to document hepatic iron content is required for participants who are currently receiving ≥8 packed red blood cell transfusions for ≥1 year or have received ≥20 packed red blood cell transfusions (cumulative). Participants who have hepatic iron content ≥7 mg Fe/ g liver dry weight by liver MRI must have a liver biopsy and histological examination/documentation of the absence of cirrhosis, bridging fibrosis and active hepatitis (≤ 90 days prior to initiation of transplant conditioning).
- Lack of clinical or radiologic evidence of a recent neurologic event (such as stroke or transient ischemic attack) by Cerebral MRI/MRA within 30 days prior to initiating transplant conditioning. Subjects with clinical or radiologic evidence of a recent neurologic event will be deferred for ≥ 6 months with repeat cerebral MRI/MRA to ensure stabilization of the neurologic event prior to proceeding to transplantation
- Documentation of participant's willingness to use approved contraception method until discontinuation of all immunosuppressive medications is to be documented in the medical record corresponding with the consent conference.
Exclusion Criteria:
HLA typing with a donor search prior to referral (consultation with HCT physician).
- If a subject has had HLA typing and a related donor search that did not identify a suitably matched relative (i.e., sibling) at any time, and also did not have an unrelated donor search, the patient will be considered eligible.
- If a subject has had HLA typing and a related donor search that did not identify a suitably matched relative (i.e., sibling) at any time and had an unrelated donor search that did not identify a suitably matched unrelated donor ≥ 1 year prior to enrollment, the patient will be considered eligible.
- If a subject has had HLA typing with no related donor search and had an unrelated donor search that did not identify a suitably matched unrelated donor ≥ 1 year prior to enrollment, the patient will be considered eligible.
- Subjects with a known HLA-identical sibling or HLA-matched unrelated donor are excluded
- Uncontrolled bacterial, viral or fungal infection in the 6 weeks before enrollment.
- Seropositivity for HIV.
- Previous HCT or solid organ transplant.
- Participation in a clinical trial in which the patient received an investigational drug or device must be discontinued at enrollment.
- A history of substance abuse as defined by version IV of the Diagnostic & Statistical Manual of Mental Disorders (DSM IV).
- Demonstrated lack of compliance with prior medical care as determined by referring physician.
- Pregnant or breast feeding females.
- Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Donor Arm
Donor Arm patients will undergo hematopoietic cell transplant. Patients with a matched unrelated donor will receive a bone marrow transplant (unless PBSC graft is pre-approved per section 2.5.1 using a preparative regimen with Busulfan, Fludarabine and rabbit ATG. Patients with an HLA-identical sibling donor can receive a transplant using one of three regimens: A. Busulfan, Fludarabine, and rabbit ATG using a bone marrow graft (preferred regimen) B. Alemtuzumab/TBI 300 cGy using a peripheral blood graft C. Alemtuzumab, fludarabine, melphalan using a bone marrow graft |
A: Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.
Other Names:
A: Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2). C: Fludarabine 30mg/m2 IV dose will be given on Days -8, -7, -6, -5, -4
Other Names:
A: r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).
Other Names:
A,B,C: Day 0 is the day of transplantation.
Other Names:
A: Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines. C: Tacrolimus at therapeutic doses through Day 180, then taper per institutional guidelines
Other Names:
A: Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2. C: Methotrexate IV 7.5 mg/m2 dose will be given on Days +1, 3, +6 following transplant
Other Names:
B: Alemtuzumab 0.03 mg/kg IV dose will be given on Day -7, Alemtuzumab 0.1 mg/kg IV dose will be given on Day -6, Alemtuzumab 0.3 mg/kg IV dose will be given on Day -5,-4,-3 C: Alemtuzumab test dose 3 mg IV once 24 hours prior to 1st dose of Alemtuzumab Alemtuzumab 10 mg IV, 15 mg IV, 20 mg IV given on Days -22 through Day -18. Alemtuzumab doses may be administered between Days -22 and -18 but are required to be on three consecutive days.
Other Names:
Total Body Irradiation 300 cGY on Day -2
Sirolimus at therapeutic doses through day 180, then taper per institutional guidelines if donor CD3+ >50%
Other Names:
C: Melphalan 140 mg/m2 IV dose will be given on Day -3
Other Names:
G-CSF 5 μg/kg/day continue until neutrophil engraftment.
Other Names:
|
Active Comparator: No-Donor Arm
No-donor arm patients will continue with standard of care per their SCD physician.
|
Continue to receive standard of care treatment per patient's SCD physician.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 2 Years
|
OS will be compared between treatment arms using a point-wise comparison at 2-years, and the survival curves will be estimated using the Kaplan Meier product limit estimator.
|
2 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Sickle Cell Disease (SCD) related events
Time Frame: 2 Years
|
Examination of the occurrence of the SCD-related events will be performed.
Exact logistic regression will be used to estimate an odds ratio of each of these events between treatment groups, assuming that at least one event occurs on study in each of the treatment groups, controlling for other patient related characteristics and individual history of the event of interest.
|
2 Years
|
Mean Pain Intensity
Time Frame: Day 28, 1 year, and 2 years
|
Mean pain intensity assessed by an electronic pain diary.
|
Day 28, 1 year, and 2 years
|
Exercise Capacity
Time Frame: Day 28, 1 year, and 2 years
|
The 6-minute walk distance (6MWD) test will be used to assess exercise capacity.
|
Day 28, 1 year, and 2 years
|
Cardiac Function
Time Frame: Day 28, 1 year, and 2 years
|
Cardiac function will be assessed by the change from baseline in Tricuspid regurgitant jet velocity (TRJV).
|
Day 28, 1 year, and 2 years
|
Pulmonary Function
Time Frame: Day 28, 1 year, and 2 years
|
Pulmonary function will be assessed by the change from baseline in Forced Expiratory Volume 1 second (FEV1).
|
Day 28, 1 year, and 2 years
|
Renal Function
Time Frame: Day 28, 1 year, and 2 years
|
Renal function will be assessed through measurements of albuminuria (urine-albumin creatinine ratio) and serum creatinine.
|
Day 28, 1 year, and 2 years
|
Health-Related Quality of Life (HRQoL)
Time Frame: Day 28, 1 year, and 2 years
|
HRQoL assessed using the NIH's PROMIS 57 instrument.
|
Day 28, 1 year, and 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Mary Eapen, MD, Center for International Blood and Marrow Transplant Research
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Anti-Bacterial Agents
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Antifungal Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Calcineurin Inhibitors
- Lenograstim
- Melphalan
- Fludarabine
- Methotrexate
- Tacrolimus
- Sirolimus
- Busulfan
- Thymoglobulin
- Antilymphocyte Serum
- Alemtuzumab
Other Study ID Numbers
- BMT CTN 1503
- 1U01HL128568-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Busulfan
-
Hospital Israelita Albert EinsteinUnknownAcute Leukemia | Immunodeficiency | Chronic Leukemia | Lymphoproliferative Disease | Myeloproliferative DiseaseBrazil
-
Institut Paoli-CalmettesUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromeFrance
-
Shanghai Public Health Clinical CenterR&D Kanglin BiotechUnknownHIV Infections | AIDSChina
-
City of Hope Medical CenterSangamo Therapeutics; California Institute for Regenerative Medicine (CIRM)Active, not recruiting
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedSarcoma | Lymphoma | Leukemia | Brain and Central Nervous System Tumors | Metastatic Cancer | Retinoblastoma | Childhood Germ Cell TumorUnited States
-
Baylor Research InstituteGenzyme, a Sanofi CompanyCompletedLeukemia | Myelodysplastic SyndromeUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Alberta Health servicesUnknownHematologic MalignancyCanada
-
Institut Paoli-CalmettesNot yet recruitingAcute Leukemia | Myeloproliferative Neoplasm | Mielodysplasic Syndrome
-
University of ArizonaCompletedHematologic Neoplasms | Multiple Myeloma | Myelofibrosis | Anemia, Aplastic | Hemoglobinuria, ParoxysmalUnited States